2018 Annual Meeting Industry Supported Symposia

0414-annual-meeting-on-Womens-cancer

2018 Annual Meeting Archives | 2018 Abstracts | 2018 Late-breaking Abstracts | 2018 Continuing Education | 2018 Schedule | 2018 Media Coverage

2018 Industry Supported Symposia

Industry Supported Symposia (ISS) are unique forums for presenting educational information to Annual Meeting attendees, free of charge. Symposia sessions are scheduled during breakfast or lunch time, allowing participants the opportunity for education and networking.

SGO does not offer Continuing Education (CE) for any of the ISS. The offering of ISS does not constitute endorsement by the SGO of the information, products or services contained therein. Registration for all symposia starts 30 minutes before the scheduled times.

Industry Supported Symposium I: Individualized Treatment Approaches for Gynecologic Cancers Based on Tumor Biology, Not Histology
Industry Supported Symposium II: Show Me the Data: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian Cancer
Industry Supported Symposium III: New Agents and Emerging Strategies in the Management of Patients with Uterine Sarcomas
Industry Supported Symposium IV: BEYOND THE GUIDELINES – Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer
Industry Supported Symposium V: The Intersection of Precision Medicine and Hereditary Cancer
Industry Supported Symposium VI: Recurrent Ovarian Cancer with Anti-VEGF Therapy
Industry Supported Symposium VII: CASES FROM THE COMMUNITY — Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer

Industry Supported Symposium I: Individualized Treatment Approaches for Gynecologic Cancers Based on Tumor Biology, Not Histology

Saturday, March 24, 2018
12:15 p.m. – 1:45 p.m.
Empire A

Faculty:
Matthew Powell, MD, Washington University School of Medicine, St. Louis, MO

Description:
A review of data from registration trials for a treatment option in certain advanced cancers.

Learning Objectives:

  • Discuss the importance of certain treatment approaches for gynecologic cancers based on certain biomarkers
  • Describe the therapeutic rationale for a treatment option in certain advanced gynecologic cancers
  • Present data from registration trials for a treatment option in patients with certain advanced gynecologic cancers

This activity is supported by Merck.

Industry Supported Symposium II: Show Me the Data: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian Cancer

Saturday, March 24, 2018
12:15 p.m. – 1:45 p.m.
Empire CD

Faculty:

  • Michael J. Birrer, MD, PhD, Harvard Medical School/ Massachusetts General Hospital, Boston, MA
  • Robert Coleman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Ursula Matulonis, MD, Dana Farber Cancer Institute, Boston, MA
  • Bradley Monk, MD, FACS, FACOG, Phoenix Biltmore Cancer Center, Scottsdale, AZ

Description:
This highly-interactive live symposium will challenge faculty to show the particular evidence that informs the treatment decisions they make (using PER’s ‘Show Me the Data’ educational format). This will aid in capturing and assessing learners’ knowledge, skills, and attitudes toward management of patients with ovarian cancer. In doing so, participants will have the chance to reflect on how they arrive at the decisions they make, how their decisions compare with the experts, whether they have a deep understanding of landmark trial results, and how to better contextualize evidence to optimize decision-making at key decision points.

REGISTER HERE

This activity is supported by Physicians Education Resource and AstraZeneca, Clovis Oncology, Myriad Genetics, and TESARO.

Industry Supported Symposium III: New Agents and Emerging Strategies in the Management of  Uterine Sarcomas

Sunday, March 25, 2018
6:30 a.m. – 7:30 a.m.
Empire A

Course Director: Neil Love, MD, Research To Practice, Miami, FL

Faculty:

  • Martee Hensley, MD, Weill Cornell Medical College, New York, NY
  • David O’Malley, MD, The Ohio State University James Cancer Center, Columbus, OH
  • Suzanne George, MD Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA

Description:
This CME symposium will focus on the diagnosis and treatment of patients with uterine sarcomas. Research To Practice president and medical oncologist Dr Neil Love will moderate the program and three investigators specializing in gynecologic sarcomas will serve as the faculty. Each investigator will be responsible for presenting a number of interesting and cases of patients currently undergoing treatment in their practice. These case presentations, which will be augmented by relevant radiologic and/or pathologic imagery, will be used to frame the program’s agenda. The event will be divided into three distinct topic modules, each featuring a blend of moderated case-based discussion and a faculty member-led presentation of relevant data and/or ongoing research related to the clinical scenarios being reviewed and their optimal application to patient care. To make the program even more relevant and engaging to those in the audience, attendees will be invited to submit their own questions and cases directly to Dr Love via text messaging. Dr. Love will present intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge.

REGISTER HERE

This activity is supported by Research to Practice and Lilly Oncology.

Industry Supported Symposium IV: BEYOND THE GUIDELINES – Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

Sunday, March 25, 2018
12:00 p.m. – 1:30 p.m.
Empire A

Course Director: Neil Love, MD, Research To Practice, Miami, FL

Faculty:

  • Kathleen Moore, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
  • Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  • Joyce F. Liu, MD, MPH, Dana-Farber Cancer Institute, Boston, MA
  • Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Description:
This CME symposium will focus on the current and future role of PARP inhibition in the management of ovarian cancer. Research To Practice (RTP) president and medical oncologist Dr. Neil Love will moderate the program, and four clinical investigators will serve as the faculty. Leading up to SGO, RTP will recruit 26 additional medical and gynecologic oncology investigators who, along with the faculty, will participate in a unique educational assessment to illuminate their general practice patterns regarding the protocol and nonprotocol role of PARP inhibitors in the treatment of patients with ovarian cancer. RTP will aggregate the results of the assessment and prioritize key data points for presentation during the program, which will be divided into four distinct modules each featuring graphical displays of the investigator survey results and a faculty member-led review of relevant research and ongoing clinical trials. To make the program more interactive and relevant to those in the room, clinician attendees will use networked iPads to complete a similar survey and their results will be displayed and juxtaposed with those of the investigators to illuminate any knowledge and practice gaps among community practitioners. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge.

REGISTER HERE

This activity is supported by Research to Practice, Abbvie, Inc., AstraZeneca Pharmaceuticals LP, Clovis Oncology, Myriad Genetic Laboratories and TESARO, Inc.

Industry Supported Symposium V: The Intersection of Precision Medicine and Hereditary Cancer

Sunday, March 25, 2018
12:00 p.m. – 1:30 p.m.
Empire CD

Course Director: Jessica Profato, MS, CGC, Ambry Genetics

Faculty:

  • Leigha Senter, MS, CGC, The Ohio State University, Columbus, OH
  • David O’ Malley, MD, The Ohio State University, Columbus, OH

Description:
Given that up to 25% of ovarian cancer is hereditary, it is recommended that all women diagnosed with epithelial ovarian, Fallopian tube, and peritoneal cancers should consider germline genetic testing. Results of germline testing are important to understand future cancer risks for the patient and their family members, so that a personalized management plan can be determined. Additionally, somatic genetic testing of an ovarian tumor can be important for therapeutic planning, such as determining eligibility for PARP inhibitors. In this course, we will review the utility of a paired tumor/germline testing model, which gives clinicians both pieces of information simultaneously, so that they can better guide healthcare decisions. This new testing model represents an intersection of precision medicine and hereditary cancer and requires thoughtful consideration of the best practices for clinical integration. We will highlight the importance of a partnership between genetic counselors and gynecologic oncologists, as testing for hereditary cancer and therapeutic planning are merged.

This activity is supported by Ambry Genetics.

Industry Supported Symposium VI: Recurrent Ovarian Cancer with Anti-VEGF Therapy

Monday, March 26, 2018
6:30 a.m. – 7:30 a.m.
Empire CD

Moderator:
Shelly Seward, MD, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI

Faculty:
Matthew Powell, MD, Washington University School of Medicine, St. Louis, MO
Sharyn Lewin, MD, FACS, Holy Name Medical Center, Teaneck, NJ and Icahn School of Medicine Mount Sinai Hospital, New York, NY

Description:
Our distinguished panel will provide a historical perspective on the importance of anti-angiogenesis and hold a case-based discussion on the clinical development of anti-VEGF therapy in the treatment of platinum-sensitive and platinum-resistant recurrent ovarian cancer.

REGISTER HERE

This activity is supported by Genentech.

Industry Supported Symposium VII: CASES FROM THE COMMUNITY — Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer

Monday, March 26, 2018
12:45 p.m. – 2:15 p.m.
Empire A

Course Director: Neil Love, MD, Research To Practice, Miami, FL

Faculty:

  • Don S. Dizon, MD, Lifespan Cancer Institute/Rhode Island Hospital/Alpert Medical School of Brown University, Providence, RI
  • Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona, College of Medicine – Phoenix, Creighton University, School of Medicine at St Joseph’s Hospital, Phoenix, AZ
  • Angeles Alvarez Secord, MD, MHSc, Duke Cancer Institute, Durham, NC
  • Lainie P Martin, MD, Fox Chase Cancer Center, Philadelphia, PA

Description:
This symposium will focus on the discussion of actual patients with ovarian cancer and the published and emerging research data informing their care. RTP president and medical oncologist Dr Neil Love will moderate the program and be joined by a panel of four clinical investigators who will serve as the faculty. In the months prior to SGO, RTP will invite a group of gynecologic oncologists practicing in a community setting to participate in a video-recording session with Dr Love to describe challenging cases from their practices and articulate any specific questions they have regarding these patients’ care. The live event will be divided into four topic modules, each beginning with the presentation of one (or more) of the pre-recorded case discussions. Following each video clip, Dr Love will invite the panelists to provide their feedback and perspectives on the optimal diagnostic and therapeutic approach, including the option of clinical trial participation. A faculty member will subsequently review the published database informing their decision-making process for patients in the clinical situations discussed. To make the program more interactive, clinician attendees will use iPads at their seats to complete a pre-meeting survey based on the cases. Survey results will be displayed throughout the program to illuminate knowledge and/or practice gaps among community-based practitioners and generate additional discussion and debate. Attendees will also be encouraged to use the iPads to submit their own questions or cases to the faculty. Dr Love will intersperse select inquiries throughout the program to foster additional conversation.

REGISTER HERE

This activity is supported by Research To Practice, Genentech BioOncology, ImmunoGen Inc. and Merck.